Skip to main content

Advertisement

Log in

Lactobacillus strains isolated from infant faeces possess potent inhibitory activity against intestinal alpha- and beta-glucosidases suggesting anti-diabetic potential

  • Original Contribution
  • Published:
European Journal of Nutrition Aims and scope Submit manuscript

Abstract

Purpose

Inhibitors of intestinal alpha-glucosidases are used therapeutically to treat type 2 diabetes mellitus. Bacteria such as Actinoplanes sp. naturally produce potent alpha-glucosidase inhibitor compounds, including the most widely available drug acarbose. It is not known whether lactic acid bacteria (LAB) colonising the human gut possess inhibitory potential against glucosidases. Hence, the study was undertaken to screen LABs having inherent alpha- and beta-glucosidase inhibitory potential.

Methods

This study isolated, screened, identified and extracted Lactobacillus strains (Lb1–15) from human infant faecal samples determining their inhibitory activity against intestinal maltase, sucrase, lactase and amylase. Lactobacillus reference strains (Ref1–7), a Gram positive control (Ctrl1) and two Gram negative controls (Ctrl2–3), were also analysed to compare activity.

Results

Faecal isolates were identified by DNA sequencing, with the majority identified as unique strains of Lactobacillus plantarum. Some strains (L. plantarum, L. fermentum, L. casei and L. rhamnosus) had potent and broad spectrum inhibitory activities (up to 89 %; p < 0.001; 500 mg/ml wet weight) comparable to acarbose (up to 88 %; p < 0.001; 30 mg/ml). Inhibitory activity was concentration-dependent and was freely available in the supernatant, and was not present in other bacterial genera (Bifidobacterium bifidum and Escherichia coli or Salmonella typhimurium). Interestingly, the potency and spectrum of inhibitory activity across strains of a single species (L. plantarum) differed substantially. Some Lactobacillus extracts had broader spectrum activities than acarbose, effectively inhibiting beta-glucosidase activity (lactase) as well as alpha-glucosidase activities (maltase, sucrase and amylase). Anti-diabetic potential was indicated by the fact that oral gavage with a L. rhamnosus extract (1 g/kg) was able to reduce glucose excursions (Area under curve; 22 %; p < 0.05) in rats during a carbohydrate challenge (starch; 2 g/kg).

Conclusion

These results definitively demonstrate that Lactobacillus strains present in the human gut have alpha- and beta-glucosidase inhibitory activities and can reduce blood glucose responses in vivo. Although the potential use of LAB such as Lactobacillus as a dietary supplement, medicinal food or biotherapeutic for diabetes is uncertain, such an approach might offer advantages over drug therapies in terms of broader spectrum activities and fewer unpleasant side effects. Further characterisation of this bioactivity is warranted, and chronic studies should be undertaken in appropriate animal models or diabetic subjects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

LAB:

Lactic acid bacteria

GRAS:

Generally recognised as safe

SE:

Sonicated extract

SN:

Supernatant

References

  1. Sales PM, Souza PM, Simeoni LA, Magalhaes PO, Silveira D (2012) α-Amylase inhibitors: a review of raw material and isolated compounds from plant source. J Pharm Pharm Sci 15(1):141–183

    Google Scholar 

  2. Kazeem MI, Dansu TV, Adeola SA (2013) Inhibitory effect of Azadirachta indica A. Juss leaf extract on the activities of α-amylase and α-glucosidase. Pak J Biol Sci 16(21):1358–1362

    Article  CAS  Google Scholar 

  3. Lebovitz HE (1997) Alpha-glucosidase inhibitors. Endocrinol Metab Clin 26(3):539–551

    Article  CAS  Google Scholar 

  4. Derosa G, Maffioli P (2012) α-Glucosidase inhibitors and their use in clinical practice. Arch Med Sci 8(5):899–906

    Article  CAS  Google Scholar 

  5. Creutzfeldt W (1999) Effects of the α-glucosidase inhibitor acarbose on the development of long term complications in diabetic animals: pathophysiological and therapeutic implications. Diabetes Metab Res Rev 15:289–296

    Article  CAS  Google Scholar 

  6. Standl E, Schnell O (2012) Alpha-glucosidase inhibitors 2012—cardio vascular considerations and trial evaluation. Diabetes Vasc Dis Res 9(3):163–169

    Article  Google Scholar 

  7. Chang J, Block TM, Guo JT (2013) Antiviral therapies targeting host ER alpha-glucosidases: current status and future directions. Antivir Res 99(3):251–260

    Article  CAS  Google Scholar 

  8. Rosak C, Mertes G (2012) Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations. Diabetes Metab Syndr Obes 5:357–367

    Article  CAS  Google Scholar 

  9. Derosa G, Maffioli P (2012) Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review. Clin Ther 34(6):1221–1236

    Article  CAS  Google Scholar 

  10. Tschope D, Hanefeld M, Meier JJ, Gitt AK, Halle M, Bramlage P, Schumm-Draeger PM (2013) The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes. Cardiovasc Diabetol 12:62

    Article  Google Scholar 

  11. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072–2077

    Article  CAS  Google Scholar 

  12. Al-Zuhair S, Dowaidar A, Kamal H (2010) Inhibitory effect of dates-extract on α-amylase and β-glucosidase enzymes relevant to non-insulin dependent diabetes mellitus. J Biochem Tech 2(2):158–160

    CAS  Google Scholar 

  13. Tundis R, Loizzo MR, Menichini F (2010) Natural products as alpha-amylase and alpha-glucosidase inhibitors and their hypoglycaemic potential in the treatment of diabetes: an update. Mini Rev Med Chem 10(4):315–331

    Article  CAS  Google Scholar 

  14. Mohamed ELH, Siddiqui MJA, Ang LF, Sadikun A, Chan SH, Tan SC, Asmawi MZ, Yam MF (2012) Potent α-glucosidase and α-amylase inhibitory activities of standardized 50% ethanolic extracts and sinensetin from Orthosiphonstamineus Benth as anti-diabetic mechanism. BMC Complement Altern Med 12:176

    Article  CAS  Google Scholar 

  15. Nair SS, Kavrekar V, Mishra A (2013) In vitro studies on alpha amylase and alpha glucosidase inhibitory activities of selected plant extracts. Eur J Exp Biol 3(1):128–132

    Google Scholar 

  16. Katekhaye SD, Nagmoti DM (2013) α-Glucosidase and α-amylase inhibitory activities of Pithecellobium dulce bark and leaves. Phytopharmacology 4(1):123–130

    Google Scholar 

  17. Yamada T, Hida H, Yamada Y (2007) Chemistry, physiological properties, and microbial production of hydroxycitric acid. Appl Microbiol Biotechnol 75(5):977–982

    Article  CAS  Google Scholar 

  18. Schwientek P, Szczepanowski R, Ruckert C, Kalinowski J, Klein A, Selber K, Wehmeier UF, Stoye J, Puhler A (2012) The complete genome sequence of theacarbose producer Actinoplanes sp. SE50/110. BMC Genomics 13:112

    Article  CAS  Google Scholar 

  19. Ramchandran L, Shah NP (2008) Proteolytic profiles and angiotensin-1 converting enzyme and alpha-glucosidase inhibitory activities of selected lactic acid bacteria. J Food Sci 73(2):M75–M81

    Article  CAS  Google Scholar 

  20. Panwar H, Rashmi HM, Batish VK, Grover S (2013) Probiotics as potential biotherapeutics in the management of type 2 diabetes—prospects and perspectives. Diabetes Metab Res Rev 29:103–112

    Article  CAS  Google Scholar 

  21. Ritchie ML, Romanuk TN (2012) A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One 7(4):e34938

    Article  CAS  Google Scholar 

  22. Chapman TM, Plosker GL, Figgitt DP (2007) Spotlight on VSL#3 probiotic mixture in chronic inflammatory bowel diseases. Bio Drugs 21(1):61–63

    CAS  Google Scholar 

  23. Anonymous or Sigma Tau Pharmaceuticals Inc. (2011) VSL#3 double strength product information sheet. http://www.vsl3.com/pdf/VSL3_DS_PL.pdf

  24. Dubernet S, Desmasures N, Gueguen M (2002) A PCR based method for identification of lactobacilli at the genus level. FEMS Microbiol Lett 214(2):271–275

    Article  CAS  Google Scholar 

  25. Turner S, Pryer KM, Miao VPW, Palmer JD (1999) Investigating deep phylogenetic relationships among cyanobacteria and plastids by small subunit rRNA sequence analysis. J Eukaryot Microbiol 46:327–338

    Article  CAS  Google Scholar 

  26. Rogall TJ, Wolters TF, Bottger EC (1990) Towards a phylogeny and definition of species at the molecular level within the genus Mycobacterium. Int J Syst Bacteriol 40:323–330

    Article  CAS  Google Scholar 

  27. Naser SM, Dawyndt P, Hoste B, Gevers D, Vandemeulebroecke K, Cleenwerck I, Vancanneyt M, Swings J (2007) Identification of lactobacilli by pheS and rpoA gene sequence analyses. Int J Syst Evol Microbiol 57:2777–2789

    Article  CAS  Google Scholar 

  28. Burington RS (1973) Handbook of mathematical tables and formulas. McGraw-Hill, New York

    Google Scholar 

  29. Meng P, Xie C, Geng P, Qi X, Zheng F, Bai F (2013) Inhibitory effect of components from Streptomyces species on alpha-glucosidase and alpha-amylase of different origin. Prikl Biokhim Mikrobiol 49(2):181–189

    CAS  Google Scholar 

  30. Onose S, Ikeda R, Nakagawa K, Kimura T, Yamagishi K, Higuchi O, Miyazawa T (2013) Production of the α-glycosidase inhibitor 1-deoxynojirimycin from Bacillus species. Food Chem 138(1):516–523

    Article  CAS  Google Scholar 

  31. Chaudet MM, Allen JL, Rose DR (2012) Expression and purification of two Family GH31 α-glucosidases from Bacteroides thetaiotaomicron. Protein Expr Purif 86(2):135–141

    Article  CAS  Google Scholar 

  32. Ley RE, Peterson DA, Gordon JI (2006) Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 124:837–848

    Article  CAS  Google Scholar 

  33. Walter J, Ley R (2011) The human gut microbiome: ecology and recent evolutionary changes. Annu Rev Microbiol 65:411–429

    Article  CAS  Google Scholar 

  34. Mountzouris KC, Kotzampassi K, Tsirtsikos P, Kapoutzis K, Fegeros K (2009) Effects of Lactobacillus acidophilus on gut microflora metabolic biomarkers in fed and fasted rats. Clin Nutr 28(3):318–324

    Article  CAS  Google Scholar 

  35. Perez-Martín F, Sesena S, Izquierdo PM, Martín R, Palop ML (2012) Screening for glycosidase activities of lactic acid bacteria as a biotechnological tool in oenology. World J Microbiol Biotechnol 28(4):1423–1432

    Article  Google Scholar 

  36. Holt SM, Teresi JM, Cote GL (2008) Influence of alternansucrase-derived oligosaccharides and other carbohydrates on alpha-galactosidase and alpha-glucosidase activity in Bifidobacterium adolescentis. Lett Appl Microbiol 46(1):73–79

    CAS  Google Scholar 

  37. Park JE, Park SH, Woo JY, Hwang HS, Cha J, Lee H (2013) Enzymatic properties of a thermostable α-glucosidase from acidothermophilic crenarchaeon Sulfolobus tokodaii strain 7. J Microbiol Biotechnol 23(1):56–63

    Article  CAS  Google Scholar 

Download references

Acknowledgments

Harsh Panwar was funded by a PhD studentship (INCN-2011-43) from Commonwealth Scholarship Commission, UK to conduct studies at Queen’s University Belfast (UK).

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Brian D. Green.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 622 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Panwar, H., Calderwood, D., Grant, I.R. et al. Lactobacillus strains isolated from infant faeces possess potent inhibitory activity against intestinal alpha- and beta-glucosidases suggesting anti-diabetic potential. Eur J Nutr 53, 1465–1474 (2014). https://doi.org/10.1007/s00394-013-0649-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00394-013-0649-9

Keywords

Navigation